Oncology Calculators
Clinical tools for oncology
Tools for staging, prognostic scores and functional assessment in oncology.
Available Calculators
Explore our collection of specialized oncology calculators
What are Oncology Calculators?
Oncology calculators are specialized clinical tools that assist oncologists and multidisciplinary teams in functional assessment, prognostic stratification, and therapeutic decision-making in cancer patients. They enable performance status assessment through scales such as ECOG and Karnofsky, calculation of tumor-specific prognostic scores, and survival estimation. Based on international oncology guidelines, multicenter clinical trials, and validated protocols, these calculators are essential for decisions on chemotherapy eligibility, treatment intensity, and communicating prognosis with patients and families.
When to Use These Tools
- Performance status assessment before starting chemotherapy
- Prognostic stratification in different cancer types
- Decision on oncological treatment intensity
- Assessment of eligibility for clinical trials
- Monitoring functional decline during treatment
- Discussion of prognosis and palliative care planning
Clinical Benefits
Frequently Asked Questions
What is the difference between ECOG and Karnofsky?
Both assess performance status. ECOG ranges from 0-5 (0=fully active, 5=death), simpler and used in oncology. Karnofsky ranges from 0-100% (100%=normal, 0%=death), more detailed. ECOG 0-1 corresponds approximately to Karnofsky 80-100%. Both validated for therapeutic decisions.
Does ECOG ≥2 contraindicate chemotherapy?
ECOG 2 is not an absolute contraindication, but requires careful risk-benefit assessment. ECOG 3-4 generally contraindicates cytotoxic chemotherapy, except in selected cases. Performance status is one factor, but general clinical condition, comorbidities, and tumor type also influence therapeutic decision.
How does performance status influence survival?
Performance status is one of the most important prognostic factors in oncology. ECOG 0-1 patients have better survival and tolerate treatment better than ECOG ≥2. Rapid PS decline may indicate tumor progression. PS is incorporated in various prognostic scores and treatment eligibility criteria.